Therapeutic Area | MeSH |
---|---|
infections | D007239 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
micafungin | ANDA | 2025-01-20 |
micafungin in sodium chloride | New Drug Application | 2025-03-07 |
micafungin sodium | ANDA | 2022-07-28 |
mycamine | New Drug Application | 2024-12-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
candidemia | EFO_1001282 | D058387 | — |
mycoses | — | D009181 | B35-B49 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Candidiasis | D002177 | — | B37 | 2 | 3 | 6 | 3 | — | 14 |
Mycoses | D009181 | — | B35-B49 | 2 | 1 | 3 | 3 | 2 | 11 |
Candidemia | D058387 | EFO_1001282 | — | 2 | 1 | 3 | 2 | — | 8 |
Invasive candidiasis | D058365 | EFO_1001283 | B37 | 2 | 2 | 3 | 1 | — | 8 |
Invasive fungal infections | D000072742 | — | — | — | — | 1 | 2 | 3 | 6 |
Aspergillosis | D001228 | EFO_0007157 | B44 | — | 3 | — | 3 | — | 6 |
Neutropenia | D009503 | — | D70 | — | — | — | 2 | 1 | 3 |
Invasive pulmonary aspergillosis | D055744 | — | B44.0 | — | 1 | — | 2 | — | 3 |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | 1 | 1 | 3 |
Leukemia | D007938 | — | C95 | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | — | 2 | — | — | 2 |
Communicable diseases | D003141 | — | — | — | — | 1 | — | 1 | 2 |
Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | — | 1 |
Fungemia | D016469 | — | B49 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Meningitis | D008581 | EFO_0000584 | G03 | — | 1 | — | — | — | 1 |
Fungal meningitis | D016921 | EFO_1000942 | — | — | 1 | — | — | — | 1 |
Acute disease | D000208 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Bone marrow transplantation | D016026 | — | — | 1 | — | — | — | — | 1 |
Immunocompromised host | D016867 | — | D84.9 | 1 | — | — | — | — | 1 |
Candida | D002175 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fever | D005334 | — | R50.9 | — | — | — | — | 1 | 1 |
Febrile neutropenia | D064147 | — | — | — | — | — | — | 1 | 1 |
Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Micafungin |
INN | micafungin |
Description | Micafungin is a cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy. It has a role as an antiinfective agent. It is an echinocandin and an antibiotic antifungal drug. |
Classification | Small molecule |
Drug class | antifungal antibiotics (undefined group) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1 |
PDB | — |
CAS-ID | 235114-32-6 |
RxCUI | — |
ChEMBL ID | CHEMBL457547 |
ChEBI ID | 600520 |
PubChem CID | 477468 |
DrugBank | DB01141 |
UNII ID | R10H71BSWG (ChemIDplus, GSRS) |